VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

Rhea-AI Summary

VBL Therapeutics (Nasdaq: VBLT), a biotechnology company focused on developing innovative therapies for challenging solid tumors, announced that CEO Dror Harats will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The presentation is scheduled for January 10 at 7:00 a.m. ET. VBL's lead candidate, ofranergene obadenovec (VB-111), is currently in a Phase 3 trial for platinum-resistant ovarian cancer. More information can be found on the company’s website.

TEL AVIV, Israel and NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune-inflammatory indications, today announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will present a corporate overview at the H.C. Wainwright BioConnect Virtual Conference being held on January 10 – 13, 2022.

H.C. Wainwright BioConnect Virtual Conference
Date: Monday, January 10^th, 2022
Time: 7:00 a.m. ET
Format: Corporate Presentation
Webcast: https://journey.ct.events/view/71cf7592-8931-4425-838e-3a61e0811eec

A link to this webcast will be available on the Events and Presentations page of the Investors section on the Company’s website at www.vblrx.com.

About VBL Therapeutics
Vascular Biogenics Ltd., operating as VBL Therapeutics (VBL), is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for difficult-to-treat malignant solid tumors and immune-inflammatory indications. VBL’s novel VTS™ gene-based platform and antibody-based monocyte targeting technology enable the creation of a pipeline of programs that harness the body’s innate biological processes to provide unique solutions for significant unmet medical needs. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111; `ofra-vec`), is an investigational, first-in-class, targeted anti-cancer gene-based agent in development to treat a wide range of solid tumors. Ofra-vec is currently being studied in a Phase 3 registration-enabling clinical trial (NCT03398655) for platinum-resistant ovarian cancer. To learn more about VBL, please visit vblrx.com or follow the company on LinkedIn, Twitter, YouTube or Facebook.

CONTACT:
Daniel Ferry
LifeSci Advisors
+1 (617) 430-7576
daniel@lifesciadvisors.com

FAQ

What is the date and time of VBL Therapeutics' presentation at the H.C. Wainwright BioConnect Virtual Conference?

VBL Therapeutics will present on January 10, 2022, at 7:00 a.m. ET.

Where can I watch the VBL Therapeutics presentation?

The presentation will be available via webcast on the company's website.

What is VBL Therapeutics focused on developing?

VBL Therapeutics is focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune-inflammatory conditions.

What is the lead product candidate of VBL Therapeutics?

The lead product candidate is ofranergene obadenovec (VB-111), which targets solid tumors.

In which clinical trial is VBL's lead candidate currently involved?

VBL's lead candidate is currently undergoing a Phase 3 trial for platinum-resistant ovarian cancer.